Peak Bio, Inc.
PKBO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 43.99 | -1,512.34 | -0.00 |
| FCF Yield | 0.00% | -85.89% | -10.28% | -4.54% |
| EV / EBITDA | 0.00 | -11,708.61 | -6.42 | -24.52 |
| Quality | ||||
| ROIC | 0.00% | 0.02% | -5.91% | 4,284.84% |
| Gross Margin | 0.00% | 99.97% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.37 | 0.57 | 1.07 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -11.37% | – | – |
| Free Cash Flow Growth | 0.00% | 37.62% | 14.04% | -414,946.90% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -7,624.20 | -0.40 | -0.16 |
| Interest Coverage | 0.00 | 0.00 | -0.02 | -790.34 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -19,979,037.85 | -12,162,593.87 | 0.00 |